The Effect of Hand Exercises on Upper Limb Volume, Quality of Life, and Hand Function in Breast Cancer Survivors
for
Breast Cancer Lymphedema
Location: Santa Fe NM, Albuquerque NM, Rio Rancho NM
Sponsor: Texas Woman's University
Sex: Female
Age: 18+
Code: NCT05983380
Recruiting
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
for
Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 3+
Code: NCT01441089
Recruiting
Dose-escalation Study of Oral CX-4945
for
Advanced Solid Tumors, Breast Cancer,
Location: Houston TX, Fort Collins CO, Loveland CO, Scottsdale AZ
Sponsor: Cylene Pharmaceuticals
Sex: All
Age: 18+
Code: NCT00891280
Phase1, Recruiting
Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
for
Anatomic Stage 0 Breast Cancer AJCC v8,
Location: Jacksonville FL
Sponsor: Mayo Clinic
Sex: Female
Age: 18+
Code: NCT06401889
Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
for
Metastatic HER2-positive Breast Cancer
Location: Boston MA, Providence RI, Quebec, Long Island City NY,
Sponsor: Jazz Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06435429
Phase3, Recruiting
Interested in new breast cancer trials?
Get alerts for new trials in your area by subscribing now
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
for
Breast Cancer
Location: Boston MA
Sponsor: Beth Israel Deaconess Medical Center
Sex: Female
Age: 21+
Code: NCT02926729
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Location: Boston MA, Montreal, Toronto, Jacksonville FL,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT06562192
Phase1, Recruiting
Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
for
Breast Cancer
Location: Milwaukee WI
Sponsor: Medical College of Wisconsin
Sex: Female
Age: 18+
Code: NCT06361940
Phase2, Recruiting
Remote Monitoring of Patient Reported Outcomes to Improve the Efficacy of the Acute Phase Radiotherapy Review Process
for
Prostate Cancer, Breast Cancer
Location: Toronto
Sponsor: University Health Network, Toronto
Sex: All
Age: 18+
Code: NCT06274892
Recruiting
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
for
DCIS, Breast Cancer, Breast Neoplasms, Sentinel Lymph Node
Location: Houston TX
Sponsor: Uppsala University
Sex: Female
Age: 18+
Code: NCT04722692
Phase3, Recruiting
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
for
Breast Cancer, Residual
Location: Rochester MN
Sponsor: Mayo Clinic
Sex: All
Age: 18+
Code: NCT04703244
Recruiting
A Beta-only IL-2 ImmunoTherapY Study
for
Advanced Solid Tumor, Unresectable Solid Tumor,
Location: Boca Raton FL, Toronto, Detroit MI, Atlanta GA,
Sponsor: Medicenna Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05086692
Phase1, Phase2, Recruiting
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
for
HER2-negative Breast Cancer Patients With Brain Metastases
Location: Stony Brook NY, Baltimore MD, Augusta GA, Chicago IL,
Sponsor: Biostar Pharma, Inc.
Sex: All
Age: 18+
Code: NCT06764940
Phase2, Recruiting
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
for
Anatomic Stage III Breast Cancer AJCC v8,
Location: Boston MA, Pittsburgh PA, Houston TX, Newport Beach CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 12+
Code: NCT05372640
Phase1, Recruiting
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer